Lipid nanoparticles are a burgeoning expertise which has huge potential to enhance chimeric antigen receptor (CAR) T cell immunotherapy. This targeted evaluation offers an summary of CAR T cell remedy – highlighting its guarantees, limitations, and challenges – and describes methods by which lipid nanoparticles (LNPs) could be rationally designed to avoid a number of the challenges. Of explicit observe are antigen presenting cell-mimetic LNPs, which have the potential to streamline the CAR T cell manufacturing course of by activating T cells and delivering the CAR transgene in a single step. Though the present medical commonplace is ex vivo CAR T cell manufacturing, in vivo CAR T cell manufacturing represents a doubtlessly transformative different. Latest improvements in every manufacturing technique are described, with a specific emphasis on methods by which LNPs might allow in vivo CAR T cell manufacturing. The evaluation concludes with a dialogue of security, immunogenicity, scalability, manufacturing, and regulatory elements which shall be important as LNP-based CAR T cell immunotherapies transfer towards medical translation.
